- H-GLU-TRP-OH
-
- $85.00
-
2026-08-16
- CAS:38101-59-6
- Min. Order: 1KG
- Purity: 0.98
- Supply Ability: 20 tons
- H-GLU-TRP-OH
-
- $8.00
-
2026-08-14
- CAS:38101-59-6
- Min. Order: 1KG
- Purity: 99%
- Oglufanide
-
- $31.00
-
2026-07-27
- CAS:38101-59-6
- Purity: 99.80%
- Supply Ability: 10g
|
| | H-GLU-TRP-OH Basic information |
| Product Name: | H-GLU-TRP-OH | | Synonyms: | alpha-glutamyltryptophan;GLU-TRP;H-GLU-TRP-OH;Ccris 8677;Glutamyl tryptophan;L-alpha-Glutamyl-L-tryptophan;L-Tryptophan, N-L-alpha-glutamyl-;NSC 334073 | | CAS: | 38101-59-6 | | MF: | C16H19N3O5 | | MW: | 333.34 | | EINECS: | | | Product Categories: | | | Mol File: | 38101-59-6.mol |  |
| | H-GLU-TRP-OH Chemical Properties |
| Melting point | 121-122℃ | | Boiling point | 738.9±60.0 °C(Predicted) | | density | 1.428 | | storage temp. | Keep in dark place,Inert atmosphere,2-8°C | | solubility | DMSO : 15.5 mg/mL (46.50 mM) | | form | Solid | | pka | 3.09±0.10(Predicted) | | color | White to off-white | | InChI | InChI=1/C16H19N3O5/c17-11(5-6-14(20)21)15(22)19-13(16(23)24)7-9-8-18-12-4-2-1-3-10(9)12/h1-4,8,11,13,18H,5-7,17H2,(H,19,22)(H,20,21)(H,23,24)/t11-,13-/s3 | | InChIKey | LLEUXCDZPQOJMY-PZILLZCRNA-N | | SMILES | C(C1=CNC2=CC=CC=C12)[C@@H](C(=O)O)NC(=O)[C@@H](N)CCC(=O)O |&1:10,17,r| |
| | H-GLU-TRP-OH Usage And Synthesis |
| Uses | Treatment of Kaposi’s sarcoma and solid tumor cancers (angiogenesis inhibitor); immunomodulator. | | Uses | H-Glu-Trp-OH, has show to have potential antiangiogenic and immunomodulating activities. It inhibits vascular endothelial growth factor (VEGF), which may inhibit angiogenesis. This agent has also been reported to stimulate the immune response to hepatitic C virus and intracellular bacterial infections. | | Definition | ChEBI: A dipeptide composed of L-glutamic acid and L-tryptophan joined by a peptide linkage. | | in vivo | Oglufanide (L-glu-L-trp) (1-100 mg/kg/day; s.c.; 10 days) has antitumor activity in immunocompetent and immunodeficient mice[4]. | Animal Model: | C57BL/6 immune competent mice, Lewis lung carcinoma (LLC) xenograft; Balb/C athymic mice, M21 human melanoma xenograft[4] | | Dosage: | 1, 10, 50 and 100 mg/kg/day | | Administration: | Subcutaneous injection, 10 days | | Result: | Resulted in a dose-dependent inhibition of LLC tumor growth in syngeneic immune competent mice and showed a dose-dependent decrease in tumor volumes of xenografts in Balb/C athymic mice implanted with M21 human melanoma cells. |
| | IC 50 | VEGFR; HCV; Human Endogenous Metabolite |
| | H-GLU-TRP-OH Preparation Products And Raw materials |
|